Lataa...
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and...
Tallennettuna:
| Julkaisussa: | Int J Cancer |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5299512/ https://ncbi.nlm.nih.gov/pubmed/27859136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30509 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|